OBJECTIVES: Polymorphisms in the vitamin K epoxide-reductase-complex-1 (VKORC1) and the cytochrome-P450-isozyme (CYP2C9) genes account for therapeutic responses to vitamin K antagonists (VKA). This study aimed to investigate the prevalence of VKORC1 and CYP2C9 polymorphisms among patients under phenprocoumon and its influence on the VKA dosage. METHODS: Patients under phenprocoumon were screened for the polymorphisms -1639G > A and 3730G > A in the VKORC1 gene and 430C > T and 1075A > C in the CYP2C9 gene by means of a StripAssay. Baseline clinical and laboratory parameters were registered. RESULTS: Among 53 patients (28 females, mean age 72.5 years), VKORC1 polymorphisms were found in 34 [-1639G > A: homozygote (n = 11), heterozygote (n = 23)] and 28 [3730G > A: homozygote (n = 7), heterozygote (n = 21)] patients. Thirteen patients were compound heterozygote. CYP2C9 polymorphisms were found in 12 [430G > T: homozygote (n = 1), heterozygote (n = 11)] and 7 [1075A > C: homozygote (n = 0), heterozygote (n = 7)] patients. Seventeen patients had at least one VKORC1 and one CYP2C9 polymorphism. Mean phenprocoumon dosage per week to achieve therapeutic anticoagulation was lower (higher) in patients with than without the VKORC1 polymorphism -1639G > A (3730G > A) or the CYP2C9 polymorphisms. Despite the presence of VKORC1 or CYP2C9 polymorphisms, mean International Normalized Ratio was not significantly different between patients with and without polymorphisms. CONCLUSIONS: Though VKORC1 and CYP2C9 polymorphisms influence the phenprocoumon dosage necessary to achieve therapeutic anticoagulation, anticoagulation is therapeutic if carefully monitored.
OBJECTIVES: Polymorphisms in the vitamin K epoxide-reductase-complex-1 (VKORC1) and the cytochrome-P450-isozyme (CYP2C9) genes account for therapeutic responses to vitamin K antagonists (VKA). This study aimed to investigate the prevalence of VKORC1 and CYP2C9 polymorphisms among patients under phenprocoumon and its influence on the VKA dosage. METHODS:Patients under phenprocoumon were screened for the polymorphisms -1639G > A and 3730G > A in the VKORC1 gene and 430C > T and 1075A > C in the CYP2C9 gene by means of a StripAssay. Baseline clinical and laboratory parameters were registered. RESULTS: Among 53 patients (28 females, mean age 72.5 years), VKORC1 polymorphisms were found in 34 [-1639G > A: homozygote (n = 11), heterozygote (n = 23)] and 28 [3730G > A: homozygote (n = 7), heterozygote (n = 21)] patients. Thirteen patients were compound heterozygote. CYP2C9 polymorphisms were found in 12 [430G > T: homozygote (n = 1), heterozygote (n = 11)] and 7 [1075A > C: homozygote (n = 0), heterozygote (n = 7)] patients. Seventeen patients had at least one VKORC1 and one CYP2C9 polymorphism. Mean phenprocoumon dosage per week to achieve therapeutic anticoagulation was lower (higher) in patients with than without the VKORC1 polymorphism -1639G > A (3730G > A) or the CYP2C9 polymorphisms. Despite the presence of VKORC1 or CYP2C9 polymorphisms, mean International Normalized Ratio was not significantly different between patients with and without polymorphisms. CONCLUSIONS: Though VKORC1 and CYP2C9 polymorphisms influence the phenprocoumon dosage necessary to achieve therapeutic anticoagulation, anticoagulation is therapeutic if carefully monitored.
Authors: Christian Oberkanins; Andreas Weinhäusel; Gernot Kriegshäuser; Anne Moritz; Fritz Kury; Oskar A Haas Journal: Clin Chem Date: 2003-11 Impact factor: 8.327
Authors: T Schalekamp; B P Brassé; J F M Roijers; E van Meegen; F J M van der Meer; E M van Wijk; A C G Egberts; A de Boer Journal: Clin Pharmacol Ther Date: 2006-12-27 Impact factor: 6.875
Authors: T Li; L A Lange; X Li; L Susswein; B Bryant; R Malone; E M Lange; T-Y Huang; D W Stafford; J P Evans Journal: J Med Genet Date: 2006-04-12 Impact factor: 6.318
Authors: Loes E Visser; Martin van Vliet; Ron H N van Schaik; A A Harrie Kasbergen; Peter A G M De Smet; Arnold G Vulto; Albert Hofman; Cornelia M van Duijn; Bruno H Ch Stricker Journal: Pharmacogenetics Date: 2004-01
Authors: Julia Kirchheiner; Mike Ufer; Ev-Charlotte Walter; Bernd Kammerer; Rainer Kahlich; Christian Meisel; Matthias Schwab; Christoph H Gleiter; Anders Rane; Ivar Roots; Jürgen Brockmöller Journal: Pharmacogenetics Date: 2004-01
Authors: Loes E Visser; Ron H N van Schaik; Martin van Vliet; Paul H Trienekens; Peter A G M De Smet; Arnold G Vulto; Albert Hofman; Cornelia M van Duijn; Bruno H Ch Stricker Journal: Thromb Haemost Date: 2004-07 Impact factor: 5.249
Authors: Janne Cadamuro; Benjamin Dieplinger; Thomas Felder; Igor Kedenko; Thomas Mueller; Meinhard Haltmayer; Wolfgang Patsch; Hannes Oberkofler Journal: Eur J Clin Pharmacol Date: 2009-12-18 Impact factor: 2.953
Authors: Martina Teichert; Loes E Visser; Andrė G Uitterlinden; Albert Hofman; Peter J Buhre; Sabine Straus; Peter A G M De Smet; Bruno H Stricker Journal: Br J Clin Pharmacol Date: 2011-11 Impact factor: 4.335
Authors: Talitha I Verhoef; William K Redekop; Ann K Daly; Rianne M F van Schie; Anthonius de Boer; Anke-Hilse Maitland-van der Zee Journal: Br J Clin Pharmacol Date: 2014-04 Impact factor: 4.335